Can a decades-old antibiotic outperform modern standards for treating stubborn bone and joint infections?
In short: Cefazolin, a first-generation antibiotic patented in 1967, is gaining renewed attention as a primary treatment for methicillin-susceptible Staphylococcus aureus. While traditionally sidelined for bone and joint infections, recent evidence suggests it may offer comparable efficacy to newer penicillins with a potentially safer profile regarding kidney health for patients.
Cefazolin belongs to the first-generation cephalosporin class and functions by disrupting bacterial cell wall synthesis. By binding to specific proteins, it prevents the creation of peptidoglycan, a structural necessity for bacteria, eventually causing them to lyse. This bactericidal action makes it effective against various gram-positive organisms, including Streptococcus and methicillin-susceptible Staphylococcus aureus (MSSA). However, it remains ineffective against MRSA, Enterococcus, and atypical bacteria, and it cannot penetrate the central nervous system to treat meningitis.
For years, medical convention favored antistaphylococcal penicillins over cefazolin for treating MSSA bacteremia, often due to historical concerns rather than definitive comparative data. Recent randomized trials, such as the 2025 CloCeBa study and the 2026 SNAP trial, have challenged this hierarchy, demonstrating that cefazolin is noninferior to penicillins for bacteremia while offering a more favorable safety profile. These findings have prompted researchers to investigate whether these benefits extend to bone and joint infections, where prolonged therapy is typically required.
A 2025 retrospective study comparing cefazolin and flucloxacillin in patients with bone and joint infections found no statistically significant difference in clinical success rates. While the study observed numerically fewer cases of acute kidney injury in the cefazolin group, the results were not definitive. Despite these promising indicators, experts note that uncertainties remain regarding high-inoculum infections and cases involving implants. As a result, while cefazolin is increasingly viewed as a rational first-line option, further prospective research is required to fully validate its role in complex orthopedic settings.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Cefazolin
- Also: Cefazolin Versus Flucloxacillin for Methicillin-Susceptible <i>Staphylococcus aureus</i> Bone and Joint Infections: A Retrospective Single-Center Comparative Study of Effectiveness and Renal Safety of Intravenous Monotherapy.
- Also: Cefazolin Versus Antistaphylococcal Penicillins in Methicillin-Susceptible <i>Staphylococcus aureus</i> Bone and Joint Infections: A Narrative Review.
To cite this card, link to https://intellectplus.co.uk/app/health-cefazolin.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Drugs and medication · More in Health · Latest · A–Z · All topics
